Hematopoietic Stem Cell Transplantation
📧 Sign up to get email alerts when something new happens for Hematopoietic Stem Cell Transplantation.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Nivestim (filgrastim) — Pfizer Europe MA EEIG
Nivestim (filgrastim) has been authorised by EMA for hematopoietic stem cell transplantation and cancer indications.
-
EMA approval · 2026-07-22EMA Authorised: Plerixafor Accord (Plerixafor) — Accord Healthcare S.L.U.
The EMA authorises Plerixafor Accord for use in multiple myeloma and hematopoietic stem cell transplantation with Accord Healthcare S.L.U. a…
-
EMA approval · 2026-07-16EMA Authorised: Zemcelpro (allogeneic umbilical cord-derived CD34- cells, non-expanded;dorocubicel) — Cordex Biologics International Limited
EMA has authorised Zemcelpro (allogeneic umbilical cord-derived CD34- cells, non-expanded; dorocubicel) for hematologic neoplasms and hemato…
-
EMA approval · 2026-07-14EMA Authorised: Zefylti (filgrastim) — CuraTeQ Biologics (Malta) Limited
Zefylti (filgrastim) has been authorised by EMA for use in neutropenia, hematopoietic stem cell transplantation, and cancer indications.
-
EMA approval · 2026-06-05EMA Authorised: Zarzio (filgrastim) — Sandoz GmbH
Authorised status for Zarzio (filgrastim) by Sandoz GmbH in the EU, covering hematopoietic stem cell transplantation and cancer indications.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Safety and Efficacy of N-Acetylcysteine Mouthwash in Prevention of Mucositis in HSCT Patients [Phase 3]
Phase 3 trial evaluating the safety and efficacy of N-Acetylcysteine mouthwash to prevent mucositis in patients undergoing hematopoietic ste…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
A completed clinical trial evaluating real-world monitoring of anti-CMV therapies in hematopoietic stem cell transplant recipients.
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Compassionate Access of the Miltenyi Device for CD34+ Cell Selection [NA]
The trial update notes compassionate-access to Miltenyi's CD34+ cell selection device for hematopoietic stem cell transplantation, with recr…
-
EMA approval · 2025-09-29EMA Authorised: Zefylti (filgrastim) — CuraTeQ Biologics s.r.o
The European Medicines Agency authorised Zefylti (filgrastim) as a biosimilar for neutropenia, hematopoietic stem cell transplantation, and …
-
EMA approval · 2025-07-08EMA Authorised: Zarzio (filgrastim) — Sandoz GmbH
The EMA authorised Zarzio, a filgrastim biosimilar from Sandoz GmbH, for use in hematopoietic stem cell transplantation and cancer indicatio…
-
CLINICAL_TRIALS research · 2025-04-20Clinical Trial Update: A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).
This is a prospective registry enrolling pediatric patients undergoing cellular therapy related to hematopoietic stem cell transplantation t…
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD
A clinical trial is evaluating posaconazole tablets as primary prophylaxis against invasive fungal disease in hematopoietic stem cell transp…
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Benefits of Intrahospital Exercise Program in Pediatric HSCT [NA]
A completed trial evaluated an intrahospital exercise program for pediatric patients undergoing hematopoietic stem cell transplantation and …
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Effects of Mesenchymal Stem Cell Supernatant on Prevention and Treatment of Skin/Mucosal Injury in Hematology Patients [NA]
Clinical trial update describes recruitment for a study evaluating mesenchymal stem cell supernatant to prevent and treat skin and mucosal i…
-
CLINICAL_TRIALS trial_result · 2023-10-06Clinical Trial Update: Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain In Patients Undergoing Allogenetic HSCT [Phase 3]
A Phase 3 trial evaluating low power laser (low-level light therapy) as prevention of oral mucositis and oropharyngeal pain in patients unde…
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: Gut Decontamination In Pediatric Allogeneic Hematopoietic [Phase 2]
Phase 2 trial update on gut decontamination in pediatric allogeneic hematopoietic stem cell transplantation with data posted after completio…
-
CLINICAL_TRIALS trial_result · 2023-09-01Clinical Trial Update: Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS [Phase 2]
Phase 2 clinical trial updating the use of letermovir for prevention of CMV infection in hematopoietic stem cell transplant recipients, eval…
-
EMA withdrawal · 2023-08-04EMA Withdrawn: Busilvex (busulfan) — Pierre Fabre Medicament
EMA withdrew Busilvex (busulfan) from the market; the product is no longer authorized in the EU.
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating tacrolimus/methotrexate with tocilizumab to prevent acute graft-versus-host disease after allogeneic hematopoietic …
-
CLINICAL_TRIALS trial_result · 2023-02-15Clinical Trial Update: Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation [Phase 4]
Phase 4 clinical study evaluating individualized administration of anti-thymocyte globulin (rATG) in haploidentical hematopoietic stem cell …
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) [Phase 3]
Phase 3 trial evaluating Efprezimod Alfa (CD24Fc, MK-7110) for prevention of acute graft-versus-host disease after myeloablative HSCT; study…
-
CLINICAL_TRIALS trial_result · 2022-05-17Clinical Trial Update: Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation [Phase 1, Phase 2]
Clinical trial updates on maraviroc for patients undergoing non-myeloablative allogeneic stem-cell transplantation (Phase 1/Phase 2).
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients [Phase 2]
Phase 2 trial evaluating the effectiveness of a COVID-19 vaccine in patients who have undergone hematopoietic stem cell transplantation.
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) [Phase 2]
Phase II trial update on Efprezimod Alfa (CD24Fc, MK-7110) for prevention of acute GVHD after myeloablative allogeneic HSCT; trial completed…
-
CLINICAL_TRIALS trial_result · 2021-04-26Clinical Trial Update: High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]
Phase 2 trial evaluating high-dose intravenous thiamine to prevent delirium in patients undergoing allogeneic hematopoietic stem cell transp…